10x Genomics Inc (TXG)
50.23
+1.19
(+2.43%)
USD |
NASDAQ |
Mar 24, 16:00
50.18
-0.05
(-0.10%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.794B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -27.19% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 11.07 |
| Price to Book Value | 7.191 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
02/17 00:35
MT Newswires
02/16 11:54
SA Breaking News
02/16 11:54
MT Newswires
02/16 11:39
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | -0.16 | -- | |
| 02/15/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/15/2023 | -- | Results | Q4 2022 | 0.21 | -0.20 | 202.1% | |
| 11/02/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/02/2022 | -- | Results | Q3 2022 | -0.07 | -0.24 | 69.33% | |
| 08/08/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/08/2022 | -- | Results | Q2 2022 | -0.25 | -0.30 | 16.47% |
*Estimated Date/Time
Earnings
Profile
Edit
| 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables. |
| URL | https://www.10xgenomics.com |
| Investor Relations URL | https://investors.10xgenomics.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Health Information Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
| Revenue (TTM) | 516.41M |
| Total Expenses (TTM) | 684.35M |
| Net Income (TTM) | -166.00M |
| Total Assets (Quarterly) | 1.029B |
| Total Liabilities (Quarterly) | 223.24M |
| Shareholders Equity (Quarterly) | 805.74M |
| Cash from Operations (TTM) | -33.61M |
| Cash from Investing (TTM) | -350.89M |
| Cash from Financing (TTM) | 15.82M |
Ratings
Profile
Edit
| 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables. |
| URL | https://www.10xgenomics.com |
| Investor Relations URL | https://investors.10xgenomics.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Health Information Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| GNOM | 15.16M USD | 7.72% |
| MSSLX | 13.68M USD | 4.01% |
| ARKG | 40.75M USD | 2.20% |
| TAAEX | 30.27M USD | 2.12% |
| ARKK | 140.85M USD | 1.93% |
| EARK.NO | 1.393M USD | 1.88% |
| EAGB.NO | 258573.0 USD | 1.78% |
| MGHRX | 82.16M USD | 1.76% |
| MSKLX | 16.10M USD | 1.74% |
| MBIRX | 22.53M USD | 1.71% |
| BTEC | 687541.0 USD | 1.34% |
| ATL1635 | 10.17M USD | 1.28% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| TXG Tweets |